ME02870B - Antitijela protiv adp-ribozil ciklaze 2 - Google Patents
Antitijela protiv adp-ribozil ciklaze 2Info
- Publication number
- ME02870B ME02870B MEP-2017-216A MEP2017216A ME02870B ME 02870 B ME02870 B ME 02870B ME P2017216 A MEP2017216 A ME P2017216A ME 02870 B ME02870 B ME 02870B
- Authority
- ME
- Montenegro
- Prior art keywords
- antibody
- antigen
- seq
- binding
- cell
- Prior art date
Links
- 102100029824 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Human genes 0.000 title claims 3
- 108010046643 ADP-ribosyl cyclase 2 Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 claims 19
- 102000036639 antigens Human genes 0.000 claims 19
- 108091007433 antigens Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 230000003013 cytotoxicity Effects 0.000 claims 2
- 231100000135 cytotoxicity Toxicity 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101710148652 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 231100000023 Cell-mediated cytotoxicity Toxicity 0.000 claims 1
- 206010057250 Cell-mediated cytotoxicity Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 101000794082 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 2 Proteins 0.000 claims 1
- 101001099051 Homo sapiens GPI inositol-deacylase Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000005890 cell-mediated cytotoxicity Effects 0.000 claims 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- AMRJKAQTDDKMCE-UHFFFAOYSA-N dolastatin Chemical compound CC(C)C(N(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(C(C)C)C(OC)CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(C=1SC=CN=1)CC1=CC=CC=C1 AMRJKAQTDDKMCE-UHFFFAOYSA-N 0.000 claims 1
- 229930188854 dolastatin Natural products 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- LZAJKCZTKKKZNT-PMNGPLLRSA-N trichothecene Chemical compound C12([C@@]3(CC[C@H]2OC2C=C(CCC23C)C)C)CO1 LZAJKCZTKKKZNT-PMNGPLLRSA-N 0.000 claims 1
- 229930013292 trichothecene Natural products 0.000 claims 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161502167P | 2011-06-28 | 2011-06-28 | |
| US2012044451 | 2012-06-27 | ||
| EP12735991.7A EP2726508B1 (en) | 2011-06-28 | 2012-06-28 | Antibodies to adp-ribosyl cyclase 2 |
| PCT/US2012/044703 WO2013003625A2 (en) | 2011-06-28 | 2012-06-28 | Antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02870B true ME02870B (me) | 2018-04-20 |
Family
ID=54359620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-216A ME02870B (me) | 2011-06-28 | 2012-06-28 | Antitijela protiv adp-ribozil ciklaze 2 |
Country Status (3)
| Country | Link |
|---|---|
| ME (1) | ME02870B (sr) |
| RS (1) | RS56431B1 (sr) |
| TN (1) | TN2013000516A1 (sr) |
-
2012
- 2012-06-28 RS RS20170919A patent/RS56431B1/sr unknown
- 2012-06-28 ME MEP-2017-216A patent/ME02870B/me unknown
-
2013
- 2013-12-12 TN TNP2013000516A patent/TN2013000516A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS56431B1 (sr) | 2018-01-31 |
| TN2013000516A1 (en) | 2015-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240052032A1 (en) | Anti-lag-3 antibodies and compositions | |
| HRP20251181T1 (hr) | Protutijela na protein gprc5d, bispecifične molekule koje vezuju antigen i koje vezuju gprc5d i cd3 te njihove primjene | |
| FI3401334T3 (fi) | Monoklonaalisia vasta-aineita Claudin-18:aa vastaan syövän hoitamiseksi | |
| CN115052893A (zh) | 抗tigit抗体和使用方法 | |
| IL250566B (en) | Anti-lag3 antibodies and antigen-binding fragments | |
| HRP20200070T1 (hr) | Humana antitijela koja vezuju limfocitni aktivacijski gen-3 (lag-3) i njihove primjene | |
| JP2020508655A5 (sr) | ||
| JP2019500892A5 (sr) | ||
| JP2009502171A5 (sr) | ||
| HRP20140341T1 (hr) | Antitijela na angiopoetin-1 i angiopoetin-2 i njihova uporaba | |
| FI3322727T3 (fi) | Humanisoituja tai kimeerisiä CD3-vasta-aineita | |
| JP2014039548A5 (sr) | ||
| JP2008541733A5 (sr) | ||
| SI2686347T1 (en) | Antibodies to cd70 | |
| HRP20211444T1 (hr) | Anti-dll3 antitijelo | |
| JP2009225799A5 (sr) | ||
| HRP20171274T1 (hr) | U potpunosti ljudska antitijela specifična za cadm1 | |
| WO2008063771A3 (en) | Anti-cd20 antibodies and methods of use | |
| CO6260104A2 (es) | Anticuerpos contra la il-25 | |
| JP2020502147A5 (sr) | ||
| RU2017145662A (ru) | Моноклональные антитела и способы их применения | |
| JP2023129433A5 (sr) | ||
| FI4200018T3 (fi) | Anti-par-2-vasta-aineet ja niiden käyttömenetelmät | |
| JP2020528765A5 (sr) | ||
| CN114502203B (zh) | 制导和导航控制蛋白及其制备和使用方法 |